SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending as the community debates whether the stock is a long-term play on financial infrastructure or a victim of increasing competition from traditional payment giants like Visa and Mastercard. While bullish investors point to potential breakthroughs from the Clarity Act and institutional adoption, others are actively trading based on significant volatility and technical gap-fill levels.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is gaining significant momentum as investors digest recent leadership additions and anticipate the official initiation of the global Phase 3 AURORA trial for non-small cell lung cancer. Community sentiment remains highly bullish, with active discussions focusing on the company's potential to disrupt the oncology market, the strategic value of its immune-activating platform, and the possibility of future acquisition by major pharmaceutical players.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing heavy selling pressure as investors scrutinize the company's aggressive debt-funded AI infrastructure expansion and potential concentration risk related to OpenAI. While the community remains divided between those viewing the steep price decline as a capitulation-driven buying opportunity and others concerned about long-term management strategy and capital allocation, sentiment is heavily influenced by intense algorithmic volatility.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors rotate into clean energy infrastructure following a strategic 380MW data center power deal that signals a shift from project proposals to active commercial execution. The community is actively debating the company's valuation gap compared to peers, while monitoring management's ability to convert pipeline demand into binding backlog and sustainable revenue.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is experiencing significant volatility and trading momentum driven by a strong re-rating as investors pivot the stock toward an AI data center power infrastructure narrative. While the community is actively debating the sustainability of these gains versus potential short-squeeze dynamics, bullish sentiment is being further fueled by recent insider buying from the CEO and speculative interest in the company's new solid-state transformer technology.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending due to significant momentum in the 'Physical AI' sector, fueled by its new strategic manufacturing agreement for its REV8 sensor family and recent high-profile infrastructure deployments ahead of the 2026 World Cup. Community sentiment is largely focused on the company's critical role as an enabler for robotics and autonomous systems, with many investors debating whether current price action represents a sustainable breakout for long-term compounding or a high-volatility momentum play.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending following a significant earnings beat and record backlog growth, which investors are weighing against soft forward guidance and margin concerns. The community is actively debating the stock's long-term potential in the defense drone super-cycle, with bullish sentiment focused on autonomous warfare demand while bears point to valuation risks and recent share price volatility.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to significant institutional accumulation and speculation surrounding its obesity pipeline, particularly as the market monitors upcoming Q3 maintenance study data. Community discussion is heavily focused on potential M&A activity, with long-term holders debating the likelihood of a buyout as the company progresses its VK2735 and VK3019 programs against sector heavyweights.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending due to intense community debate over its depressed valuation, with many investors pointing to significant share buybacks and strong free cash flow as a potential setup for a long-term turnaround or a future buyout. While bullish sentiment centers on the company's massive user base and potential for new ad-driven revenue, a vocal segment of the community remains frustrated by stagnant price action and perceived management incompetence, fueling ongoing speculation about institutional manipulation.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense community debate driven by its recent inclusion in the Russell 3000 index and ongoing speculation surrounding potential defense-sector supercycles and counter-drone contract opportunities. While bulls are focused on the company's autonomous systems partnerships and backlog growth, the stock is experiencing significant volatility as market participants clash over the impact of recent share dilution and heavy short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

@BuyNHold4riches 1) Best-performing carotid stent based on FDA clinical data (historic 0.95% MAE rate in C-GUARDIANS).

2) Best-in-class platform for BOTH traditional stenting &amp; TCAR (100% success rate in CG-II).

MicroNet mesh tech is completely disrupting a multi-billion dollar market.

Chris

StockTwits for iOS

 1) Best-performing carotid stent based on FDA clinical data (historic 0.95% MAE rate in C-GUARDIANS).

2) Best-in-class platform for BOTH traditional stenting & TCAR (100% success rate in CG-II).

MicroNet mesh tech is completely disrupting a multi-billion dollar market.

Mag.x - Arcuy

@arcuy @BuyNHold4riches 2) “Best-performing carotid stent based on FDA clinical data” — plausible, but needs caveat.
The company claims CGuard Prime had the lowest 30-day and 1-year primary endpoint MAE rates of any pivotal carotid intervention study. That claim is supported by their FDA approval release/SEC filing, but it is still a cross-trial comparison, not a head-to-head trial.  
For context, ENROUTE/TCAR ROADSTER II reported 1.7% 30-day stroke/death/MI, while ROADSTER 3 reported 0.9% ITT / 0.6% per-protocol in standard-risk patients, so “best” depends heavily on endpoint, risk group, and population.  

3) “Best-in-class for BOTH traditional stenting &amp; TCAR” — not fully proven.
For traditional carotid stenting, the data are strong. For TCAR, C-GUARDIANS II showed 100% acute device success in 50/50 patients and zero 30-day deaths/strokes/MIs, but the TCAR version was still under FDA PMA supplement review with potential approval in H2 2026.

 2) “Best-performing carotid stent based on FDA clinical data” — plausible, but needs caveat.
The company claims CGuard Prime had the lowest 30-day and 1-year primary endpoint MAE rates of any pivotal carotid intervention study. That claim is supported by their FDA approval release/SEC filing, but it is still a cross-trial comparison, not a head-to-head trial.  
For context, ENROUTE/TCAR ROADSTER II reported 1.7% 30-day stroke/death/MI, while ROADSTER 3 reported 0.9% ITT / 0.6% per-protocol in standard-risk patients, so “best” depends heavily on endpoint, risk group, and population.  

3) “Best-in-class for BOTH traditional stenting & TCAR” — not fully proven.
For traditional carotid stenting, the data are strong. For TCAR, C-GUARDIANS II showed 100% acute device success in 50/50 patients and zero 30-day deaths/strokes/MIs, but the TCAR version was still under FDA PMA supplement review with potential approval in H2 2026.

Steven

@Thespectator @BuyNHold4riches Good pushback. You are 100% right that cross-trial comparisons aren&#39;t head-to-head, and the populations differ (e.g., standard-risk vs. high-risk). Also correct on the TCAR PMA timeline.But the bull thesis on $NSPR doesn&#39;t rely on a single trial—it&#39;s the tech itself.Conventional stents (even the Enroute used in ROADSTER) are standard open-cell or closed-cell designs. InspireMD&#39;s MicroNet dual-layer mesh completely changes the game by physically trapping the plaque.Even if ROADSTER 3 hit a phenomenal 0.6% PP rate, doctors still worry about late embolic events and plaque protrusion after the patient leaves the table. MicroNet provides a structural safety net that bare-metal stents physically cannot replicate.You&#39;re right that H2 2026 approval for the 80cm TCAR system is the catalyst we are waiting for. If the MicroNet tech translates its traditional stenting performance over to TCAR permanently, it is going to take massive market share.

InspireMD Inc

 Good pushback. You are 100% right that cross-trial comparisons aren't head-to-head, and the populations differ (e.g., standard-risk vs. high-risk). Also correct on the TCAR PMA timeline.But the bull thesis on 

 doesn't rely on a single trial—it's the tech itself.Conventional stents (even the Enroute used in ROADSTER) are standard open-cell or closed-cell designs. InspireMD's MicroNet dual-layer mesh completely changes the game by physically trapping the plaque.Even if ROADSTER 3 hit a phenomenal 0.6% PP rate, doctors still worry about late embolic events and plaque protrusion after the patient leaves the table. MicroNet provides a structural safety net that bare-metal stents physically cannot 

're right that H2 2026 approval for the 80cm TCAR system is the catalyst we are waiting for. If the MicroNet tech translates its traditional stenting performance over to TCAR permanently, it is going to take massive market share.

@arcuy @BuyNHold4riches  be careful with anything claimed by nspr management , they tend to exaggerate the pros and downplay the cons, just like those surprising recalls, always take what they say with an extra grain of salt

  be careful with anything claimed by nspr management , they tend to exaggerate the pros and downplay the cons, just like those surprising recalls, always take what they say with an extra grain of salt

@Thespectator @BuyNHold4riches Let’s not move the goalposts. Management and product are two completely different things. My point wasn&#39;t based on NSPR press releases—it’s based on independent, peer-reviewed clinical science.The PARADIGM study and DW-MRI/OCT imaging data are objective medical facts published by independent doctors. Those studies prove a physical reality: bare-metal stents allow plaque prolapse, and MicroNet completely blocks it.You can criticize management or the delivery system recall all you want (and that&#39;s fair), but the implant itself is a phenomenal piece of engineering. The clinical data on the device stands on its own

Buddha

80+ free IT tools for developers, sysadmins, students, and support teams. JSON formatter, DNS lookup, password generator, and more. No signup required.

it.you

 Let’s not move the goalposts. Management and product are two completely different things. My point wasn't based on NSPR press releases—it’s based on independent, peer-reviewed clinical science.The PARADIGM study and DW-MRI/OCT imaging data are objective medical facts published by independent doctors. Those studies prove a physical reality: bare-metal stents allow plaque prolapse, and MicroNet completely blocks 

 can criticize management or the delivery system recall all you want (and that's fair), but the implant itself is a phenomenal piece of engineering. The clinical data on the device stands on its own

@arcuy @BuyNHold4riches bad management can ruin even the world’s best product especially when they can get well compensated by milking the “investors”

 bad management can ruin even the world’s best product especially when they can get well compensated by milking the “investors”

@Thespectator @BuyNHold4riches No argument there. Bad management ruins great products all the time, and biotech is full of examples. But that just proves my point: we agree the product itself is excellent. I&#39;m looking at this strictly from a medical technology standpoint, and the science behind the implant is phenomenal. Glad we could separate the engineering from the corporate noise.To be completely honest, I don&#39;t like Marvin&#39;s performance. I don&#39;t like Paul&#39;s performance either. As shareholders, we should absolutely do something about it. The product will do great in the market—the real question is whether management will actually let us capture some of that value or just dilute it away

 No argument there. Bad management ruins great products all the time, and biotech is full of examples. But that just proves my point: we agree the product itself is excellent. I'm looking at this strictly from a medical technology standpoint, and the science behind the implant is phenomenal. Glad we could separate the engineering from the corporate noise.To be completely honest, I don't like Marvin's performance. I don't like Paul's performance either. As shareholders, we should absolutely do something about it. The product will do great in the market—the real question is whether management will actually let us capture some of that value or just dilute it away

@arcuy @BuyNHold4riches the sad reality is retails can’t do anything to the management, they simply don’t care about you or me, and I suppose they got even more tricks to screw up retails, just wait and see

 the sad reality is retails can’t do anything to the management, they simply don’t care about you or me, and I suppose they got even more tricks to screw up retails, just wait and see

@Thespectator if you are so convinced then what’s your angle here ? Are you a short or just a spectator mother Teresa ?

 if you are so convinced then what’s your angle here ? Are you a short or just a spectator mother Teresa ?

@BioBuddha I hold a grudge against this greedy and inept management, you have a problem with that?

 I hold a grudge against this greedy and inept management, you have a problem with that?

@Thespectator no i don’t. I have it with $PPBT aka $KTOV